Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.
